Hematology & Blood Cancer
Hematology & Blood Cancer
Advertisement
Cecilia BrownHematology & Blood Cancer | April 8, 2024
Researchers analyzed data from more than 1 million people to determine blood cancer mortality rates from 2000-2020.
Read More
Cecilia BrownConferences | April 5, 2024
There is a “lack of consistency” among patient-reported outcome measures used to evaluate CML treatments.
Cecilia BrownConferences | April 5, 2024
The analysis of 10 clinical trials and 1 prospective cohort study provides a "benchmark for future studies" of the treatment.
Cecilia BrownConferences | April 9, 2024
Even highly educated patients feel "inadequately informed about the purpose, implications, and language around testing."
Cecilia BrownConferences | April 9, 2024
It was important to develop the model because fatigue has been an "overlooked side effect" due to its "subjective nature."
Cecilia BrownLeukemia | March 26, 2024
The label expansion was supported by data from the phase III PhALLCON study.
Cecilia BrownMultiple Myeloma | March 18, 2024
The withdrawal comes 2 years after the FDA granted accelerated approval to the treatment.
Cecilia BrownHematology & Blood Cancer | April 16, 2024
Educational content focused on the pre-HSCT work-up process, chemotherapy, and transplant admission expectations.
Cecilia BrownLeukemia | March 8, 2024
The approval is for pediatric patients older than 1 year with relapsed or refractory CD22-positive B-cell precursor ALL.
Cecilia BrownHematology & Blood Cancer | March 6, 2024
Nurses reported that they were “keenly aware of how disruptive the environment is for patients and their families."
Cecilia BrownPatient Voice | March 4, 2024
The researchers said the study is the first to evaluate sexual health outcomes after CAR-T in young adults.
Krystal Waldrup, BSN, RN, OCNNews | February 29, 2024
Learn how an institution started a standalone CAR-T cell therapy program without a pre-existing BMT program.
Cecilia BrownNews | February 7, 2024
Psychosocial care and support are critical parts of cancer care, according to the International Psycho-Oncology Society.
Cecilia BrownMultiple Myeloma | February 14, 2024
It was important to develop the model because outcomes are heterogenous, with overall survival ranging from months to years.
Cecilia BrownHematology & Blood Cancer | January 15, 2024
Researchers developed and piloted a novel phone-delivered positive psychology intervention called PATH.
Cecilia BrownSickle Cell | January 12, 2024
Nurse-administered and self-administered screening techniques can show different results.
Cecilia BrownSickle Cell | January 12, 2024
People with SCD are at a “high risk of hospitalization and mortality from COVID-19."
Cecilia BrownSickle Cell | January 11, 2024
RBC survival data may “inform hemoglobin composition thresholds required to reverse the phenotype after gene therapy."
Cecilia BrownSickle Cell | January 11, 2024
Acute pain vaso-occlusive episodes are the top cause of emergency department visits among people with SCD.
Cecilia BrownSickle Cell | January 11, 2024
Researchers said involving patients "is essential to improve participation and meet the real needs of the patient ...
Advertisement
Advertisement
Advertisement